Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets

Nature Communications(2017)10.1038/ncomms16022Source: DataRank Database

Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets is a research paper published in Nature Communications (2017). On theSindex it has a DataRank of 0.821. It has been cited 237 times.

N/A

0.821DataRank · unranked

Scored on demand from live citation data

Open Access237 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: goldTopics (46)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.821

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (10)

Li Ma ORCID,Hyojung Paik,Marina Sirota ORCID,Wei Wei ORCID,Mei-Sze Chua

Live enrichment

PubMed:28699633 PMC:PMC5510182

NCI NIH HHS

Grant: U24 CA195858

NIGMS NIH HHS

Grant: R01 GM079719

National Institutes of Health

Grant: 5R01GM079719-04

Enabling new discoveries in pharmacogenomics through a genomic date-driven nosolo

goldLicense: cc-by

publisherhttps://www.nature.com/articles/ncomms16022.pdf

publisherhttps://www.nature.com/articles/ncomms16022

publisherhttp://www.nature.com/doifinder/10.1038/ncomms16022

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/5510182

repositoryhttps://doaj.org/article/483c6f7f7ae94ba0a71118ed5cb81f74

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

AnimalsHumansMiceMice, NudeLiver NeoplasmsPyrvinium CompoundsAntineoplastic AgentsXenograft Model Antitumor AssaysSystems BiologyGene ExpressionFemaleHep G2 Cells

Keywords

Liver CancerScienceNude610Gene ExpressionMice, NudeAntineoplastic AgentsArticleMicePyrvinium CompoundsRare DiseasesGeneticsAnimalsHumansCancerBiomedical and Clinical SciencesLiver DiseaseSystems BiologyHuman GenomeQLiver NeoplasmsPharmacology and Pharmaceutical SciencesHep G2 CellsBiological SciencesXenograft Model Antitumor AssaysOrphan DrugGood Health and Well Being5.1 PharmaceuticalsFemaleDigestive DiseasesBiotechnology

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Knowledge graph analytics platform with LINCS and IDG for Parkinson's disease target illumination

10.6084/m9.figshare.18318346.v1figshare

Additional file 1 of Knowledge graph analytics platform with LINCS and IDG for Parkinson's disease target illumination

10.6084/m9.figshare.18318346figshare

Additional file 4 of Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma

10.6084/m9.figshare.21385811.v1figshare

Additional file 4 of Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma

10.6084/m9.figshare.21385811figshare

Additional file 1 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597419.v1figshare

Additional file 1 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597419figshare

Additional file 2 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597422.v1figshare

Additional file 2 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597422figshare

Additional file 3 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597425.v1figshare

Additional file 3 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597425figshare

Additional file 4 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597428figshare

Additional file 4 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597428.v1figshare

Additional file 5 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597431.v1figshare

Additional file 5 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597431figshare

Additional file 6 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597434.v1figshare

Additional file 6 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597434figshare

Additional file 7 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597437.v1figshare

Additional file 7 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597437figshare

Additional file 9 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597443.v1figshare

Additional file 9 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing

10.6084/m9.figshare.23597443figshare

Related Papers (10)

Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data

N/A

1.0DataRank · unranked

Science Translational Medicine(2011)

co-cited

10.1126/scitranslmed.3001318

Comprehensive analysis of normal adjacent to tumor transcriptomes

Top 3%

6.6DataRank

Nature Communications(2017)

co-citedsame journal

10.1038/s41467-017-01027-z

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

Top 2%

8.9DataRank

Nature Communications(2019)

co-citedsame journal

10.1038/s41467-019-09234-6

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

N/A

1.0DataRank · unranked

Nature Medicine(2019)

co-cited

10.1038/s41591-019-0654-5

limma powers differential expression analyses for RNA-sequencing and microarray studies

N/A

1.6DataRank · unranked

Nucleic Acids Research(2015)

co-cited

10.1093/nar/gkv007

In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma

N/A

1.9DataRank · unranked

Oncotarget(2016)

co-cited

10.18632/oncotarget.13385

xCell: digitally portraying the tissue cellular heterogeneity landscape

N/A

1.3DataRank · unranked

Genome Biology(2017)

co-cited

10.1186/s13059-017-1349-1

DrugBank 5.0: a major update to the DrugBank database for 2018

Top 2%

8.4DataRank

Nucleic Acids Research(2017)

co-cited

10.1093/nar/gkx1037

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

Top 1%

10.4DataRank

Nucleic Acids Research(2016)

co-cited

10.1093/nar/gkw377

The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019

Top 1%

9.6DataRank

Nucleic Acids Research(2018)

co-cited

10.1093/nar/gky1120

Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets

FAIR Checklist

DataRank Breakdown

Authors (10)

Funding (3 grants)

Open Access

Topics

Linked Datasets (25)

Annotations (Europe PMC)

Related Papers (10)